【摘 要】
：
In confronting the pandemic,the most obvious strategy is to make treatment as widely available as possible.Beyond treatment,however,the focus should be on prevention.Large inflows of new funding prese
【机 构】
：
Special Adviser to the UN Secretary-General and UN Special Envoy for HIV/AIDS in Asia and the Pacifi
【出 处】
：
2006中国天津世界艾滋病日科技会议
论文部分内容阅读
In confronting the pandemic,the most obvious strategy is to make treatment as widely available as possible.Beyond treatment,however,the focus should be on prevention.Large inflows of new funding present new challenges,e.g.how to approach sensitive questions of prejudice and discrimination,and how to ensure that appropriate attention is paid to prevention.Prevention measures extend to empowerment of women; universal access to reproductive health information and services,and integrating RAl and HIV/AIDS services.The Global Fund is uniquely poised to help provide leadership with its demonstrated advantages:low overheads,it is performance-based,and it is flexible.It meets felt needs; two-thirds of all investments are in low-income countries; it has scaled up rapidly and it is effective.Continued support at the international as well as national levels is vital to meet the goals of the MDG.
其他文献
Viruses,by definition,are obligate intracellular pathogens and therefore,successful vaccination must induce cellmediated immunity for effective control and/or prevention of disease.Since HIV-1 is pred
FusoGen Pharmaceuticals,Inc.is a leading Chinese biotech company based in Tianjin and Beijing,China.The company was founded in 2002 by Jason G.Zhou,an expert in structural biology and computer-assiste
The HIV-1 reverse transcriptase (RT) has been a successful target for chemotherapeutic intervention.However,new drugs are urgently needed for systemic or for topical use as a microbicide due to the ev
NIFEVIROC,a small molecular compound,is a proprietary drug candidate which is developed by TARGETDRUG and holds great promise in inhibiting HIV-1 replication in infected paitents.Preclinical studies s
The continuing emergence of resistant strains of the human immunodeficiency virus type 1 (HIV-1) makes the search for new anti-HIV-1 agents very urgent One of the most attractive target for selective
Until the end of 2005,twenty-seven drags targeted to the human immunodeficiency virus (HIV) have been approved by the U.S.Food and Drug Administration (FDA).Although great progress has been made in th
Human Immunodeficiency virus (HIV) is composed of two viral types:HIV-1 and HIV-2.HIV-1 is pandemic.Sequence analysis of HIV-1 has allowed to classify this virus into three groups:M (major),O (outlier
Combination therapy with reverse transcriptase and protease inhibitors is the most common current treatment of HIV-1 infection.Despite the success of this therapy,it has adverse effects and drug resis
We identified,characterized and defined the molecular mechanism of two novel inhibitors of HIV-1.These small molecules are effective against multiple steps of the viral life cycle.They inhibit HIV-1 a